Evidence map›Paper›PMID 35285667›Full record

ReviewJournal of the American Heart Association2022

Phenotype-Directed Management of Hypertension in Pregnancy.

Kelsey McLaughlin, John W Snelgrove, Laura E Sienas, Thomas R Easterling, John C Kingdom, Catherine M Albright

Open access · goldAbstract readReview
In one paragraph

Review in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. ISUOG Consensus Statement on maternal hemodynamic assessment in hypertensive disorders of pregnancy and fetal growth restriction.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025
    Article
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. The Update of Fetal Growth Restriction Associated with Biomarkers.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Kelsey McLaughlinDepartment of Obstetrics and Gynecology Division of Maternal-Fetal Medicine Sinai Health SystemUniversity of Toronto Toronto Canada.ORCID 0000-0001-9441-0606
John W SnelgroveDepartment of Obstetrics and Gynecology Division of Maternal-Fetal Medicine Sinai Health SystemUniversity of Toronto Toronto Canada.ORCID 0000-0002-7128-8916
Laura E SienasDepartment of Obstetrics and Gynecology Division of Maternal-Fetal Medicine University of Washington Medical Center Seattle WA.
Thomas R EasterlingDepartment of Obstetrics and Gynecology Division of Maternal-Fetal Medicine University of Washington Medical Center Seattle WA.ORCID 0000-0002-6015-5632
John C KingdomDepartment of Obstetrics and Gynecology Division of Maternal-Fetal Medicine Sinai Health SystemUniversity of Toronto Toronto Canada.ORCID 0000-0002-7411-5535
Catherine M AlbrightDepartment of Obstetrics and Gynecology Division of Maternal-Fetal Medicine University of Washington Medical Center Seattle WA.ORCID 0000-0002-5459-8904
University of Toronto · CAUniversity of Washington Medical Center · US

Funding

CIHR
6 · The paper itself

Abstract

Hypertensive disorders of pregnancy are among the most serious conditions that pregnancy care providers face; however, little attention has been paid to the concept of tailoring clinical care to reduce associated adverse maternal and perinatal outcomes based on the underlying disease pathogenesis. This narrative review discusses the integration of phenotype-based clinical strategies in the management of high-risk pregnant patients that are currently not common clinical practice: real-time placental growth factor testing at Mount Sinai Hospital, Toronto and noninvasive hemodynamic monitoring to guide antihypertensive therapy at the University of Washington Medical Center, Seattle. Future work should focus on promoting more widespread integration of these novel strategies into obstetric care to improve outcomes of pregnancies at high risk of adverse maternal-fetal outcomes from these complications of pregnancy.

Indexed as

HypertensionPregnancy ComplicationsFemaleHumansPhenotypePlacenta Growth FactorPregnancyPregnancy OutcomePlacenta Growth Factorantihypertensive agentsfemale sexhemodynamic monitoringhumanshypertension, pregnancy‐inducedplacenta growth factorpregnancy

Identifiers

PMID35285667
PMCPMC9075436
OpenAlexW4220687802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.